⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of REGENXBIO Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
REGENXBIO Inc.
↗Rockville, USA
REGENXBIO is a clinical-stage biotechnology company pioneering the field of adeno-associated virus (AAV) gene therapy. The company utilizes its proprietary NAV Technology Platform, which includes over 100 novel AAV vectors, to develop one-time gene therapy treatments for rare, retinal, and neurodegenerative diseases.
Headquartered in Rockville, Maryland, REGENXBIO operates with end-to-end capabilities, including in-house research, clinical development, and commercial-ready manufacturing. The company advances both internal pipeline programs and strategic licensing partnerships with major pharmaceutical companies to address significant unmet medical needs.
CLASSIFICATION
SIZE & FINANCIALS
Employees:201-500
Revenue:$170M
Founded:2008
Ownership:public
Status:operating
FUNDING
Stage:Post-IPO
Investors:Formerly VC-backed
STOCK
Exchange:NASDAQ
Ticker:RGNX
Market Cap:$0.49B
PIPELINE
Stage:Phase 3
Lead Drug Stage:Phase 3
Modalities:Gene therapy
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:AbbVie (ABBV-RGX-314 development), Nippon Shinyaku (MPS programs)
COMPETITION
Position:Challenger
Competitors:Novartis, BlueRock Therapeutics, ProQR Therapeutics, Asklepios BioPharmaceutical
LEADERSHIP
Key Executives:
Curran M. Simpson - President and CEO
Mitchell Chan - CFO
Olivier Danos - Chief Scientific Officer
Board Members:Ken Mills (Chairman), Daniel Tassé, Allan Fox, Jean Bennett
LINKS
Website:regenxbio.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with REGENXBIO Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.